USPTO serial 87802718
IOMX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 5, 2021
- Examiner
- WATTS-FITZGERALD,CAITLIN C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with IOMX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*
Plus Government fees of $975
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Planegg/Martinsried, DE
Planegg/Martinsried, DE
Planegg/Martinsried, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Allison R. Imber
Allison R. Imber Allen, Dyer, Doppelt & Gilchrist, P.A.255 S. Orange Avenue, Suite 1401Orlando, FL 32801United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals, medical and veterinary preparations, pharmaceutical preparations and formulations, and medicated health preparations, all of the aforesaid goods for use in the treatment or prevention of human and animal diseases, disorders and conditions, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, disorders and conditions, and for use in the treatment or prevention of complications associated with such diseases, disorders and conditions; Pharmaceuticals, medical and veterinary preparations, pharmaceutical preparations and formulations, and medicated health preparations, all of the aforesaid goods for use in the treatment or prevention of human and animal diseases, disorders and conditions, namely, bone sensory, viral, urinary, renal, metabolic or central nervous system diseases, disorders and conditions, and for use in the treatment or prevention of complications associated with such diseases, disorders and conditions; Pharmaceuticals, medical and veterinary preparations, pharmaceutical preparations and formulations, and medicated health preparations, all of the aforesaid goods for use in the treatment or prevention of human and animal diseases, disorders and conditions, namely, infectious, auto-immune or immune-related, cell-proliferative or oncologic diseases, disorders and conditions, cancers, tumours and metastases, and for use in the treatment or prevention of complications associated with such diseases, disorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, bone sensory, viral, urinary, renal, metabolic or central nervous system diseases, disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, infectious, auto-immune or immune-related, cell-proliferative or oncologic diseases, disorders and conditions, cancers, tumours and metastases, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions | ACTIVE | — |
| 010 | Diagnostic apparatus for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions, specifically, sample-analysis devices and related data-analysis software sold as a unit, nucleic acid-analysis or protein-analysis diagnosis apparatus, and diagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit; Diagnostic apparatus for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, bone sensory, viral, urinary, renal, metabolic or central nervous system diseases disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions, specifically, sample-analysis devices and related data-analysis software sold as a unit, nucleic acid-analysis or protein-analysis diagnosis apparatus, and diagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit; Diagnostic apparatus for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, infectious, auto-immune or immune-related, cell-proliferative or oncologic diseases, disorders and conditions, cancers, tumours and metastases, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions, specifically, sample-analysis devices and related data-analysis software sold as a unit, nucleic acid-analysis or protein-analysis diagnosis apparatus, and diagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit | ACTIVE | — |
| 042 | Scientific services, namely, scientific research, analysis and testing in the fields of biology, chemistry or medicine, as well as in the fields of immunology, oncology, molecular biology, cellular biology, biochemistry and medicinal chemistry; Scientific services, namely, scientific research, analysis and testing in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents, and diagnostic apparatus; Design and development of computer software for database management, cloud-storage of data, data-management, data-query, data-analysis and data-presentation, for the query, analysis and presentation of the sequence or structure of molecules, or for predicting or providing a medical diagnosis or prognosis, as well as for controlling and managing patient medical information, with any of the aforementioned services for use in the fields of biology, chemistry or medicine, as well as for use in the fields of immunology, oncology, molecular biology, cellular biology, biochemistry and medicinal chemistry; Design and development of computer software for database management, cloud-storage of data, data-management, data-query, data-analysis and data-presentation, as well as for the query, analysis and presentation of the sequence or structure of molecules, or for predicting or providing a medical diagnosis or prognosis, with any of the aforementioned services for use in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents, and diagnostic apparatus | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by IOmx Therapeutics AG
- Other trademarks owned by IOmx Therapeutics AG
- Other trademarks owned by IOmx Therapeutics AG
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named IOMX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 5, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Feb 8, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 8, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Feb 8, 2024 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Feb 8, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 8, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 8, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 8, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 6, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 6, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 6, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 6, 2023 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Mar 6, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 6, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 6, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 8, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 8, 2021 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Oct 8, 2021 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Oct 8, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 8, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 5, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 20, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 20, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 30, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 15, 2020 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Sep 11, 2020 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Sep 10, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 25, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 24, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 24, 2020 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jul 9, 2020 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 9, 2020 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 9, 2020 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 24, 2020 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Dec 18, 2019 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jun 18, 2019 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Dec 12, 2018 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Dec 12, 2018 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Dec 12, 2018 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 10, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 10, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 3, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 4, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 4, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 4, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 4, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 3, 2018 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Mar 30, 2018 | ALIE | ASSIGNED TO LIE | — |
| Mar 16, 2018 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Feb 26, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 22, 2018 | NWAP | NEW APPLICATION ENTERED | — |